### 2026-08-11 16:16 UTC 自动交叉验证
- P&L: -1.9%
- 4大师速览: NEUTRAL
BUFFETT: WATCH, strong data network effect but lacks proven pricing power.
MUNGER: Mistake if proprietary multimodal data is commoditized by general-purpose AI.
DUAN(段永平): Yes, if it becomes the essential operating system for precision medicine.
LI_LU(李录): Speculative compounding potential with an elevated risk of permanent loss.
OVERALL: NEUTRAL
- Serenity速览: BULLISH
CHOKEPOINT_INTACT: YES
REASON: The proprietary multimodal data library and closed-loop clinician integration continue to scale, reinforcing the network effect moat.
OVERALL: BULLISH
- **升级触发**: 从未做过深度复核
- **付费深度判断** ($0.5533): **结论：这次升级是误报，不是 TEM 论文走坏。HOLD。**

查了状态文件后情况很清楚：TEM 不是卫星仓的论文持仓，而是今天 13:31 UTC 由 `daily_open_daytrade.py` 按催化剂建的日内仓，@~$55.85、权重仅 1.52%，买入理由写得很明确——CellCarta 把 Tempus 纳入 CDx 商业化实验室网络（第二家商业合作方，真实业务增量而非纯情绪）。"从未做过深度复核 / no saved thesis" 触发的原因是它压根就没有 `reports/TEM/thesis.md`，和 7-25 那次 TEL 的 "BROKEN" 是同一类假阳性：crossvalidate 在扫它不该扫的日内仓。

本地两个框架的判断本身都不算错，但都答错了题——它们评的是 Tempus 未来 3–5 年的护城河（专有多模态数据网络效应 vs. 缺乏定价权），而这个仓位的兑现周期是"数日"。芒格那条反面意见（专有多模态数据被通用 AI 商品化）是真实的长期风险，我认可，但它在几天内不会兑现，不构成现在减仓的理由；Serenity 的 CHOKEPOINT_INTACT=YES 说的是同一个网络效应还在扩张，与今天的 CellCarta 增量方向一致，逻辑自洽。

建议 **HOLD**，且由日内脚本自己的退出规则接管（+2% 上限 / +0.1% 地板保护 / 收盘前强制平仓），不要因为这条升级做基于论文的 TRIM/EXIT——上次 08-06/08-07 "合理轮换吃掉全部盈利"就是这么来的。

两件顺带要处理的：
1. `crossvalidate_satellite.py` 应把日内仓（`daily_open_daytrade` 建的仓）排除在"缺失论文"升级条件之外，否则每天开盘后都会刷一遍这种噪音。
2. ⚠️ 更值得注意：`.daily_open_daytrade_DRYRUN_state.json` 的 action_log 里有 `[实盘同步] 买入 TEM 17.5438股`、以及 GRAL 的 `[实盘同步失败] insufficient buying power`——按 CLAUDE.md，实盘 cron 应该是暂停的、只跑 DRY_RUN。dry-run 脚本似乎仍在向实盘下单。要不要我去查一下这条实盘同步链路是从哪来的？（这个我不会自作主张改，先问你。）

我没能取到 TEM 当前报价（`quote.sh` 的执行权限被拒了），所以上面没算浮盈浮亏；要看实时盈亏的话批一下这条命令就行。


### 2026-08-11 20:12 UTC 自动交叉验证
- P&L: -0.5%
- 4大师速览: NEUTRAL
BUFFETT: WATCH; strong multimodal data moat but lacks consistent earnings power.
MUNGER: Mistake if the "closed-loop" network fails to scale or faces regulatory collapse.
DUAN(段永平): Yes; fundamental infrastructure for the next decade of precision medicine.
LI_LU(李录): NEUTRAL; immense compounding potential offset by high risk of permanent loss.
OVERALL: NEUTRAL
- Serenity速览: BULLISH
CHOKEPOINT_INTACT: YES
REASON: The proprietary multimodal data loop between clinicians and labs continues to scale, deepening the moat against pure-play diagnostic competitors.
OVERALL: BULLISH


### 2026-08-12 00:05 UTC 自动交叉验证
- P&L: -0.6%
- 4大师速览: NEUTRAL
BUFFETT: HOLD; strong network effect via multimodal data repository creates a widening moat.
MUNGER: Mistake if the data fails to translate into scalable, repeatable clinical revenue.
DUAN: Yes; represents a fundamental structural shift toward precision medicine.
LI_LU: WATCH; high compounding potential offset by significant burn and execution risk.
OVERALL: NEUTRAL
- Serenity速览: BULLISH
CHOKEPOINT_INTACT: YES
REASON: The proprietary integration of multimodal clinical and molecular data remains a high-barrier moat for precision medicine.
OVERALL: BULLISH


